Unidentified Investor's questions to Scinai Immunotherapeutics Ltd (SCNI) leadership • Q2 2024
Question
An unidentified investor requested an update on the development timeline and next steps for the anti-IL-17 nanoAb program for plaque psoriasis.
Answer
CEO Amir Reichman detailed a multi-step plan, starting with a longer in-vivo animal study in September to optimize the dosing schedule, concluding in Q1 2025. This will be followed by toxicology studies. The Phase I/IIa clinical trial in humans is slated to begin in the second half of 2025, with a data readout expected in Q1 2026. Reichman noted a successful trial would create a strong position for partnership discussions and that the IL-17 nanoAb platform has potential for other indications.